Share Name Share Symbol Market Type Share ISIN Share Description
Xenetic Bio LSE:XEN London Ordinary Share GB00B08NWV55 ORD 0.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 6.00p 0.00p 0.00p - - - 0 06:30:09
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.2 -3.4 -0.9 - 24.48

Xenetic Bio Share Discussion Threads

Showing 4426 to 4440 of 4450 messages
Chat Pages: 178  177  176  175  174  173  172  171  170  169  168  167  Older
Broker saying 'XEN' could reach $10,but any research not in public domain yet.
Seeking Alpha has no idea why at this point.Movements here are absolutely crazy, but maybe a small fund taking a punt.Hope its not a P&D.
Hmmmm .....
poppa wobbler
Interest stirring here for what its worth to UK holders !
Now we have 9 cents drop to 3.3101 from yesterday's $4.00. This company should be quoted on Noddydaq.
51c or 14.53% improvement so far today to $3.47 on 9 shares traded, when the 52 week range is stated as 3.30-29.37 says everything you need to know here,Best to regard the value of this stock as worthless. Mind you, Trump did win the US election, so miracles do happen, but not here I suspect.
the Circus goes on.. uplist to Nasdaaq yet still cant get calue or trade through my broker TD.. what a shambles this stock is. Anyone else having the same issue?
Agreed Trotters.
Finally.. feels like and eternity.. typical the day they list is the day before the US election.. FFS, you couldn't make it up Held for years will hold for another 12 months to let this play out
Of modest interest for most UK punters I expect, given the previous huge dilution. Still better than a kick in the pants.
10/10/2016 Xenetic Biosciences (XBIO) Announces Favorable Data from Third Cohort of ErepoXen Phase 3 in Anemia Xenetic Biosciences, Inc. (OTC: XBIO) announced positive topline data from the third cohort of its Phase 2 dose-escalation study with its lead drug candidate ErepoXen for the treatment of anemia in pre-dialysis chronic kidney disease patients. This trial is being conducted for Xenetic by Novotech (Australia) Pty Ltd. The third cohort of the Phase 2, open label, sequential dose finding study to evaluate the safety, pharmacodynamics (PD) and pharmacokinetics (PK) of multiple doses of ErepoXen was launched in October 2015 and was conducted in Australia and South Africa. As in the previous cohorts, patients in the third cohort of this study received injections of ErepoXen every two weeks until hemoglobin levels reached therapeutic levels. The patients then received injections of ErepoXen every 4 weeks (extended dosing interval) during maintenance for a total trial time of 17 weeks. Professor Simon D Roger M.D., FRACP, Director of Renal Medicine, Gosford Hospital, Australia and Principal Investigator of the study, said, “The results achieved with ErepoXen® in these individuals with chronic kidney disease expand on the initial two cohorts, and, continue to demonstrate a reassuring safety profile. I am very pleased about the potential for ErepoXen® to act as a therapeutic agent to treat these anemic patients and look forward to the continued study of this compound to achieve further results.” The data from the second cohort show that 11 of 12 (91%) of the enrolled patients had an increase in hemoglobin levels over time, and that in 9 of 12 (75%) of the enrolled patients, hemoglobin levels rose into the targeted therapeutic range (10-12 g/dL). The third cohort was designed to achieve a faster rate of rise of hemoglobin than the previous cohorts, but still less than the recommended 1g/dL per 4 weeks. Data from the third cohort showed that 11 of 14 (79%) of the enrolled patients had an increase in hemoglobin levels over time, and that 10 of 14 (71%) of the enrolled patients, hemoglobin levels rose into the therapeutic range of 10-12 g/dL. The cohort average hemoglobin level reached the therapeutic range between weeks 4 and 6 after initiation of therapy. Hemoglobin levels were then maintained within the therapeutic range for the remainder of the 17-week study. This compares favorably with the first two cohorts, which showed an increase in the average hemoglobin levels over the course of the 17-week study. In all three cohorts, ErepoXen® was generally well tolerated and there was only one possibly related significant adverse event in cohort 3. In none of the cohorts has there been an increase the immune response as measured by IgG or IgM antibodies to PSA, EPO or PSA-EPO. Overall the safety profile of ErepoXen to maintain red blood cell production and prevent anemia remains favorable. Initial PK results confirmed the original product serum half-life of greater than 400 hours. “The completion of this third cohort study is a noteworthy step in the development pathway of ErepoXen. We continue to see exciting data being generated and believe ErepoXen has potential to be a promising treatment option for anemic patients,” stated Scott Maguire, CEO. “While the data from this study are positive and maintained the safety profile, we believe that we have not yet reached the most effective clinical dose for these patients. We are therefore continuing this Phase 2 study and look forward to sustained good news. More broadly speaking, the results we are announcing today have increased our confidence in the potential of our patented PolyXen® technology which has significantly changed the biological half-life of epoetin (an injectable form of endogenous erythropoietin) while maintaining its pharmacological activity in humans. We expect that this technology may be applicable to a large variety of therapeutic compounds, not only modifying their biological properties, but also generating new patent exclusivities.”;
.................... ZIKA and the need for newer and better molecular assays There will be many other diseases affecting babies identified over the coming months OCT 6, 2016 In a new study published today in the New England Journal of Medicine Carlos Pardo together with Beatriz Parra and a consortium of doctors and scientists from Colombia and Johns Hopkins Hospital examined 68 patients from six Colombian hospitals. Of the 68 Guillain-Barré; patients, 66 had symptoms of Zika infection before they came down with GBS. They tested 42 of the patients for Zika virus using sensitive molecular assays, and found that 17 of them (40%) had detectable Zika virus. Guillain-Barré; syndrome is a very rare but very deadly illness, with a mortality rate of 5% if you receive the absolute best care–and higher mortality otherwise. Its cause is generally unknown, but now we have strong evidence that Zika virus infection is one of its causes. Drs. Pardo and Parra also found evidence of a possible link between GBS and both Zika and dengue virus: 32 out of 37 Guillain-Barré; patients who were tested had antibodies to both Zika and dengue, suggesting that they may have suffered two successive infections by these viruses, which are genetically similar to one another. In an editorial accompanying the new study, Jennifer Frontera and Ivan da Silva write that although the new study supports the link between Zika and GBS, confirmatory evidence in more patients will strengthen the (possible) causal association. They warn that “the Zika virus pandemic is just beginning in North America and Africa, and an increase in the incidence of the Guillain-Barré; syndrome may follow.” Steven Salzberg is the Bloomberg Distinguished Professor of Biomedical Engineering, Computer Science, and Biostatistics at Johns Hopkins University.
............................................ ZIKA ....................................... Zika vaccine research firm attracts private funding offers after clinching grant 08/09/2016 Private investors are queueing up to fund a small British pharmaceutical company that holds promise of developing the world's first Zika vaccine. Cambridge-based firm Excivion has gained attention since clinching a Government grant worth £500,000 that will help jump-start vaccine development for the mosquito-borne virus. Chief executive and immunologist Peter Laing says he has never seen this kind of interest from private investors during his 22-year career. "I've had people contact me on the website, offering to fund the company. I've never heard of that before, never heard of it in the history of my work in the biotechnology industry," he told the Press Association. Excivion is seeking private backers to keep research going once government funding runs out. The half a million pound grant, issued by the Small Business Research Initiative and Innovate UK, is meant to be spent within 12 months. It is part of the Department of Health's plans to invest up to £10 million in two competitions that would prompt development of vaccines for infectious diseases and technologies. The company is aiming to bring a vaccine to market by 2023, and Excivion staff are working around the clock to develop it. Mr Laing has contracted around 30 scientists across India, the US, Germany and the UK to supplement the company's two-person operation back in Cambridge. This strategy has allowed Mr Laing to recruit the best industry specialists and keep costs down. In mid-August, the company announced a partnership with US-based Nasdaq-listed pharma firm Xenetic Biosciences to develop technologies to deliver the vaccine. Excivion is working with ''micro-encapsulation'' technology that could increase vaccine strength and hopes to eliminate the need for refrigeration, which would allow the vaccine to be stockpiled for pandemic emergencies. "There's a lot of moral pressure to do everything right, and to make sure that you've thought everything through," he said. "It's been been quite stressful actually, because we want to take best advantage of the funding and do right by the British public who ultimately fund this work." Mr Laing and his business partner have put their own money into the company, but he says it is small in comparison. The chief executive is confident Excivion will secure further funding, given the level of interest so far. Mr Laing stopped short of revealing the total number of private offers Excivion has received, but said the company is now eyeing alternative fundraising methods. "In fact we're even considering setting up a parallel charity which would ensure that 100% of those funds could be applied to research and development." There are plans to license the potential Zika vaccine "quite early" to a larger pharmaceutical company that would commit to bringing the product to market. Multiple licenses could be issued in a bid to keep costs low for the countries that need the Zika vaccine most. However, the chief executive made clear that Excivion is not looking for a buy-out. "I want to be a larger company but I don't want to sell the company. I want the company to be in Britain, creating employment, and developing new vaccines."
Re post 1341 and 1342 Note the references to Peter Laing of excivion ltd Regards what he has previously achieved at Lipoxen ( which was the old name for Xenetic Biosciences when it was based in the UK ) Check out his achievements were and are now. They are set to earn $'s for XEN and this new deal re Zika could now add to that see hTTp://!intellectual-property/cfvg So it looks a good tie up/deal pre floatation to me Track Record of Invention Peter Laing, CEO, has a strong track record of invention that has given rise to notable licensing deals with major pharma and biotech companies. As a Lecturer in Immunology at the Univesity of Nottingham he filed one of the first patents on luminescent DNA sequencing; at Peptide Therapeutics plc (later Acambis) as Director of Research he pioneered 'Molecular Vaccine Design' patenting peptide mimics of the capsular polysaccharide of the group-B meningococcus as vaccine immunogens; at Lipoxen plc he was responsible for development of the 'Virtual Conjugate Vaccine' that was licensed to Serum Institute of India Ltd for a 14-component pneumococcal vaccine (wherein liposomal formulation takes the place of chemical conjugation); at Lipoxen (now Xenetic) as Chief Operating Officer he was also responsible for their 'Co-Delivery' technology which exploits DNA and protein representations of an antigen in the selfsame particle effecting dramatic improvements in vaccine potency (allowing single-dose), exemplified with influenza and hepatitis-B vaccines. At Lipoxen he also developed long-acting versions of factor-VIII in collaboration with Baxter, and a next-generation EPO (ErepoXen) for anaemia, now in phase-III. At United Therapeutics Corp/Europe Ltd he was in charge of their hepatitis-C programme and an inventor of diagnostic and therapeutic patents in the field of flaviviruses, notably UV4B - an oral broad-spectrum antiviral agent now licensed to Emergent for dengue. These finely tuned inventive skills are now dedicated to Excivion in pursuit of its New Pharmaceutical Model.
Some here might not be aware that SHIRE is now a XEN shareholder Also that Virexxa is the second drug in Xenetics pipeline that has been granted FDA " ORPHAN " status News prior to the Nasdaq Floatation seems to be gathering pace ... USA investors with the USA markets now doing very well will like this Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa® in Endometrial Cancer AUGUST 19, 2016 LEXINGTON, Mass.-- Xenetic Biosciences, Inc. (OTCQB: XBIO) (“Xenetic̶1; or the “Company”;), a biopharmaceutical company developing next-generation biologic drugs and novel orphan oncology therapeutics, announced today that an Investigational New Drug (IND) application for the Company's product candidate, Virexxa® (sodium cridanimod), has been allowed to proceed by the U.S. Food and Drug Administration (FDA). This enables Xenetic to initiate a Phase 2 clinical study of Virexxa in conjunction with progestin therapy for the treatment of endometrial cancer in women with recurrent or persistent disease who have failed progestin monotherapy. The primary objective of the study is to assess the anti-tumor activity of Virexxa. Secondary objectives include assessment of additional efficacy, pharmacokinetic and safety/tolerability parameters. Further translational objectives are to observe the effect of Virexxa in combination with progestins, on the levels of progesterone receptor (PrR) and activated progesterone receptors (APrR) in tumor tissues. “This IND clearance enables us to proceed with our Phase 2 study in endometrial cancer and represents a major step forward in our clinical development of Virexxa,” stated Scott Maguire, CEO. “We believe Virexxa® to be a next-generation therapeutic that has the potential to provide women with no additional treatment options a novel and effective therapy." Endometrial cancer is the most common malignancy of the female genital tract and represents a major health concern, as overall five-year survival rates have not improved over the past three decades. Annually in the United States, an estimated 60,050 patients are diagnosed with endometrial cancer and 10,470 deaths occur from this disease, representing 1.8% of all cancer deaths in the US. The incidence of endometrial cancer is on the rise with a lifetime risk of approximately 3% while the disease-specific mortality of endometrial carcinoma has been rising in the last 25 years. Endometrial cancer patients whose tumors no longer express progesterone receptors are not candidates for progestin-based therapy. Patients who fail monotherapy with progestins have no additional treatment options. Virexxa may improve sensitivity to progestin therapy in subjects with advanced or recurrent PrR-negative tumors. About Virexxa® Virexxa is a small-molecule immunomodulator and interferon inducer which, in preliminary studies, has been shown to increase progesterone receptor (PrR) expression in endometrial tissue. Restoration of PrR expression may re-sensitize endometrial tumor tissue to progestin therapy in previously unresponsive tumors. Virexxa is currently being studied in an ongoing Phase 2 multi-national study enrolling 58 subjects with documented evidence of progesterone receptor negative (PrR-negative) endometrial cancer as determined by tumor biopsy. This study is being conducted in conjunction with Pharmsynthez PJSC (St. Petersburg Russia) and its subsidiary AS Kevelt (Tallinn, Estonia). For more information on this Phase 2 study of Virexxa for the treatment of PrR-negative endometrial cancer, please visit and reference Identifier NCT02064725. About Xenetic Biosciences Xenetic Biosciences, Inc. is a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen®, designed to develop next generation biologic drugs by extending the efficacy, safety and half-life of biologic drugs. Xenetic's lead product candidates include ErepoXen™, a polysialylated form of erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and FDA orphan designated oncology therapeutics Virexxa® and Oncohist™ for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia. Xenetic is also working together with Shire plc (formerly Baxalta Incorporated, a spinoff of the biopharmaceuticals business from Baxter Healthcare SA and Baxter Healthcare Corporation) to develop a novel series of polysialylated blood coagulation factors, including a next generation Factor VIII. This collaboration relies on Xenetic's PolyXen technology to conjugate polysialic acid (“PSA”) to therapeutic blood-clotting factors, with the goal of improving the pharmacokinetic profile and extending the active life of these biologic molecules. Shire is one of the Company's largest shareholders having invested $10M in the common stock of the Company during 2014. The agreement is an exclusive research, development and license agreement which grants Shire a worldwide, exclusive, royalty-bearing license to Xenetic's PSA patented and proprietary technology in combination with Shire’s proprietary molecules designed for the treatment of blood and bleeding disorders. Under the agreement, Xenetic may receive regulatory and sales target payments for total potential milestone receipts of up to $100 million plus royalties on sales. In addition, Xenetic is developing a broad pipeline of clinical candidates for next generation biologics and novel oncology therapeutics in a number of orphan disease indications. For more information, please visit the company's website at and connect on Twitter, LinkedIn, Facebook and Google+.
Chat Pages: 178  177  176  175  174  173  172  171  170  169  168  167  Older
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180116 21:38:13